Status:
COMPLETED
Efficacy and Safety of BGG492 in the Treatment of Migraine
Lead Sponsor:
Novartis
Conditions:
Migraine
Eligibility:
All Genders
18-60 years
Phase:
PHASE2
Brief Summary
This study will assess the efficacy and safety of BGG492 used to treat migraine pain.
Eligibility Criteria
Inclusion
- Diagnosis of moderate to severe migraine for at least 1 year
- At least 1 migraine episode, but not more 15 migraine days per month
- Past use of triptans
- Migraine onset before 50 years of age
Exclusion
- Diagnosis of basilar, ophthalmoplegic or hemiplegic migraine.
- More than 6 non-migraine headaches per month
- Patients receiving migraine prophylaxis treatment
- Patients receiving regular treatment with psychoactive drugs
- Smokers
- Patients with a very high or low body weight Other protocol-defined inclusion/exclusion criteria may apply
Key Trial Info
Start Date :
April 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2010
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT00892203
Start Date
April 1 2009
End Date
August 1 2010
Last Update
December 17 2020
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
California Clinical Trials, 1560 Chevy Chase Drive, Suite 140
Glendale, California, United States, 91206
2
California Clinical Trials, 15625 Lakewood Boulevard
Paramount, California, United States, 90723
3
Novartis Investigative Site
Berlin, Germany
4
Novartis Investigative Site
Essen, Germany